SEARCH

SEARCH BY CITATION

References

  • 1
    Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:15711576.
  • 2
    MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765774.
  • 3
    Chrysant SG. Vascular remodeling: the role of angiotensin converting enzyme inhibitors. Am Heart J. 1998;135(suppl 1):S21S30.
  • 4
    Takai S, Jin D, Sakaguchi M, et al. Chymase dependent angiotensin II formation in human vascular tissue. Circulation. 1999;100:654658.
  • 5
    Ihara M, Urata H, Kinoshita A, et al. Increased chymase dependent angi otensin II formation in human atherosclerotic aorta. Hypertension. 1999;33:13991405.
  • 6
    Hollenber NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998;32:387392.
  • 7
    Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial. The Losartan Heart Failure Survival Study (ELLITE II). Lancet. 2000;355:15821587.
  • 8
    Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:16671675.
  • 9
    Pfeffer MA, McMurray JJ, Velasquez EJ, et al., for the Valsartan in Acute Myocardial Infarction Trial (VALIANT) investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:18931906.
  • 10
    Pfeffer MA, Swedberg K, Granger CD, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759766.
  • 11
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851860.
  • 12
    Brenner BM, Cooper ME, Dezeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861869.
  • 13
    Juillera L, Nussberger J, Menard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990;16:564572.
  • 14
    Unger T. Pharmacology of the AT1 receptor blockers. Blood Press Suppl. 2001;10 (suppl 3):510.
  • 15
    Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: Are there differences in efficacy? Am J Hypertens. 2000;13:418426.
  • 16
    Chrysant SG, Weber MA, Wang A, et al. Factorial design to assess the safety and efficacy of olmesartan medoxomil and hydrochlorothiazide combination therapy. Am J Hypertens. 2004;17:252259.
  • 17
    Chrysant SG, Holtzman J, Lewin A, et al. Results of a pilot dose-ranging trial of valsartan in patients with essential hypertension [abstract]. Am J Hypertens. 1996;9:121A.
  • 18
    Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996;18:797810.
  • 19
    Pool J, Oparil S, Hedner T, et al. Dose-response antihypertensive efficacy of valsartan: a new angiotensin II receptor blocker. Clin Ther. 1998;20:11061114.
  • 20
    Neutel J, Weber M, Pool J, et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther. 1997;19:447458.
  • 21
    Martin J, Krum H. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease. Pharmacol Res. 2002;46:203212.
  • 22
    Bremner AD, Baur M, Oddou-Stock P, et al. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens. 1997;19:12631285.
  • 23
    Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multi-dose, double-blind, placebo-controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 1998;12:861866.
  • 24
    Hall WD, Montoro R, Littlejohn T, et al. Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension. Clin Drug Invest. 1998;16:203210.
  • 25
    Schmidt A, Adam SA, Kolloch R, et al. Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension. Blood Press. 2001;10:230237.
  • 26
    Palatini P, Malacco E, Fogari R, et al. A multicenter, randomized, double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. J Hypertens. 2001;19:16911696.
  • 27
    Scholze J, Probst G, Bertsch K, et al. Valsartan alone and in combination with hydrochlorothiazide in general practice: results from two postmarketing surveillance studies involving 54,928 patients with essential hypertension. Clin Drug Invest. 2000;20:17.
  • 28
    Waeber B, Aschwanden R, Sadesky L, et al. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. J Hypertens. 2001;19:20972104.
  • 29
    Hall J, Marbury T, Gray J, et al. Long-term safety, tolerability and efficacy of valsartan: results from one and two year trials. J Drug Assess. 1998;1:281293.
  • 30
    Chrysant SG, Wombolt DG, Feliciano N, et al. Long-term efficacy, safety, and tolerability of valsartan and hydrochlorothiazide in patients with essential hypertension. Curr Ther Res Clin Exp. 1998;59:762772.
  • 31
    Chrysant SG. Fixed low-dose drug combination for the treatment of hypertension. Arch Fam Med. 1998;7:370376.
  • 32
    Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med. 1990;322:15611566.
  • 33
    Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats: lisinoprilmediated regression of myocardial fibrosis. Hypertension. 1996;28:269275.
  • 34
    Diez J, Querejeta R, Lopez B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction in left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105:25122517.
  • 35
    Thurmann PA, Kenedi P, Schmidt A, et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 1998;98:20372042.
  • 36
    Malmgvist K, Ohman KP, Lind L, et al. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Cardiovasc Pharmacol. 2003;42:719726.
  • 37
    Dahlof B, Devereux RB, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:9951003.
  • 38
    Cuspidi C, Muiesan ML, Valagussa L, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens. 2002;20(11):22932300.
  • 39
    Kjeldsen SE, Julius S, Brunner H, et al. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Blood Press. 2001;10:8391.
  • 40
    Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies. Challenges in improving prognosis. Am J Cardiol. 2002;89:18A25A.
  • 41
    Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure. Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40:970975.
  • 42
    Viberti G, Wheeldon NM, for the Micro-Albuminuria Reduction With Valsartan (MARVAL) Study Investigators. Micro-albuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure independent effect. Circulation. 2002;106:672678.
  • 43
    Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139:901906.
  • 44
    The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC 7 Report. JAMA. 2003;289:25602572.
  • 45
    Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.